Capital expenditureswere $12 million and cash dividends of $58 million were paid during the secondquarter of fiscal 2009

Capital expenditureswere $12 million and cash dividends of $58 million were paid during the secondquarter of fiscal 2009. * Excluding restructuring charges, non-GAAP diluted EPS from continuingoperations was $0.21, compared to $0.18 in the immediately prior quarter, and$0.44 in the year-ago period * Net cash provided by operating activities was$76 million. * Diluted earnings per share (EPS) from continuing operations was $0.18,compared to $0.08 in the immediately prior quarter, and $0.44 in the year-agoperiod. * Excluding restructuring charges, non-GAAP operating income from continuingoperations was $70 million, or 14.7% of revenue, compared to $61 million, or12.9% of revenue, in the immediately prior quarter, and $157 million, or 24.2%of revenue, in the year-ago period.

* Operating income from continuing operations was $58 million, or 12.2% ofrevenue, compared to $20 million, or 4.1% of revenue, in the immediately priorquarter, and $157 million, or 24.2% of revenue, in the year-ago period. * Operating expenses were$204 million, a decrease of $46 million, or 18%, fromthe immediately prior quarter, and a decrease of $35 million, or 15%, from thesame period one year ago. * Excluding restructuring charges, non-GAAP operating expenses were $192million, a decrease of $16 million, or 8%, compared to the immediately priorquarter, and a decrease of $47 million, or 20%, compared to the same period oneyear ago. * Gross margin was 55.1% of revenue, compared to 56.4% of revenue in theimmediately prior quarter, and 61.0% of revenue in the year-ago period.

Thesequential decrease in gross margin was primarily due to lower manufacturingutilization and end market revenue mix. * Restructuring charges of $12 million were recorded in the second quarter offiscal 2009 as part of the plan to reduce infrastructure expenses across thecompany. In addition, a more complete table covering prior periods is availableon the Analog Devices Investor Relations web site at: investor.analog . For moreinformation regarding the breakout of revenue by end market and product type forthe second quarter of fiscal 2009, please see Schedules D and E of thisdocument. Results of Operations for the Second Quarter of Fiscal 2009The table reconciling the Company`s non-GAAP financial results to GAAP financialresults is provided in this release on Schedule F.* Revenue was $475 million, approximately flat with the immediately priorquarter and a decrease of 27% from the same period one year ago. (NYSE: ADI), a global leader in high-performancesemiconductors for signal processing applications, today announced financialresults for the second quarter of fiscal 2009, which ended May 2, 2009. (NYSE: ADI)* Revenue was $475 million* Gross margin was 55.1% of revenue* Diluted EPS from continuing operations was $0.18, which includes a $0.03 per share impact from restructuring* Cash and short-term investments at the end of 2Q09 totaled $1.3 billion* Board of Directors declared a cash dividend of $0.20 per share* Financial results will be discussed via conference call today at 5:00 pmAnalog Devices, Inc.

NORWOOD, Mass.–(Business Wire)–Analog Devices, Inc. In CLL8, previously untreated patients who received Rituxanplus chemotherapy had a 69 percent improvement in PFS (41 percent riskreduction, hazard ratio=0.59; p. The abnormalcells outnumber the normal white blood cells, making it difficult for the bodyto fight infection. The applications are based on positive results from two of the largest globalPhase III clinical trials conducted in patients with CLL. The randomized,comparative studies, known as CLL8 and REACH, showed that Rituxan plus standardchemotherapy for CLL extended the time patients lived without the canceradvancing (progression-free survival or PFS) compared to those receivingchemotherapy alone. It is a slow-growing disease that occurs when too manyabnormal white blood cells develop in the blood and bone marrow. CLL is the most common type of adult leukemia, accounting for one-third of allleukemias in the U.S.

and Biogen Idec (Nasdaq:BIIB) today announced that the companiessubmitted two supplemental Biologics License Applications (sBLAs) to the U.S.Food and Drug Administration (FDA) for Rituxan® (rituximab) plus standardchemotherapy for people with previously untreated or treated chronic lymphocyticleukemia (CLL). The companies will request a priority review, and if granted,anticipate the FDA will make a decision within six months. orPublic RelationsJim Peavy, 908-439-2200, ext. orRachelle Morrow, 908-439-2200, ext. Copyright Business Wire 2009.